Dr.Shelley Boyd Research - High Risk Dry AMD Clinic
| Total Number of Gifts: 3 | |
| Total Value of Gifts: $225.00 |
- Tell a friend about
- Create a page like this
- Please bookmark this page.
Recent Donors
In memory Of Bill Sutton (husband of Sue Sutton)
Mr. Thomas Thompson
Mrs. Susanne Sutton
Full Donor List
Age-related Macular Degeneration (AMD)
AMD is the leading cause of irreversible blindness in the world and is growing globally.
Our Mission is to find a treatment for the dry form of AMD, which currently has no treatment options. Our Vision is to do this efficiently and effectively through the art of translation, bringing novel treatments from the scientific bench to the patient in the clinic, by strategically aligning our development program to address the field's greatest needs.
With your help, we can accelerate a treatment for dry AMD
About Dr Shelley Boyd, MD, FRCS(C)
Dr. Shelley Boyd is an ophthalmologist & clinician-scientist focused on "dry" Age Related Macular Degeneration (AMD). She is an Assistant Professor with the University of Toronto in the Departments of Ophthalmology & Vision Sciences (DOVS) and Laboratory Medicine & Pathobiology (LMP) and is cross-appointed to Biomedical Engineering at McMaster University. She is the founding director of Canada's only dedicated "High Risk Dry AMD Clinic", a clinical research facility at St. Michael's Hospital, where she uses specialized imaging and a patient-centered registry to understand and compare the different subtypes of dry AMD.
Working at the Keenan Research Centre of the Li Ka Shing Knowledge Institute, her lab focuses on finding new therapies for this blinding disease. Dry AMD effects 85% of patients with late disease and no treatments exist.
Dr. Boyd was previously Head of the Ocular Angiogenesis research program, world-wide, for Novartis pharmaceuticals (Basel, Switzerland) where she led the pre-clinical and translational aspects of the Lucentis program, the standard-of-care treatment for "wet" AMD. Working with St. Michael's Hospital and with the goal of turning science into medicine she recently founded a biotech company, Translatum Medicus inc (TMi), that uniquely combines her background in science, medicine and the pharmaceutical industry with the hospital's mission to be leaders in knowledge translation.
If you think this page contains objectionable content, please inform the system administrator.